Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Pick a strategy above and run the backtest to see its simulated performance on FDMT.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
Shares of 4D Molecular Therapeutics are up 0.24% at $12.59. The company is worth $695.52M, number 3514 out of 3753 on our list.
The 52-week range is $6.96 to $16.93. Today's price is about 56% of the way from the low to the high. Holders are ahead 30.3% over twelve months, but down 2.3% across the last three months.
Price is below the 50-day average ($13.56) but above the 200-day ($10.49); RSI is 36, and the last 30 sessions moved at roughly 49% annualized volatility.
In the quarter ended Jun 2026 the company brought in $3.78M of revenue, up 25,106.7% from a year earlier, and a net loss of $72.94M.
9 analysts follow the stock and the average call is "buy". The mean target, $30.43, sits 141.7% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 3752 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
9 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
FDMT is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $30.43, 141.7% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $18.02, so shares trade 30.1% below that estimate. On earnings multiple, it sits in the 38th percentile of its own five-year valuation range (cheaper than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -10.7% | Bearish |
| Price vs 50-day average | -7.2% | Bearish |
| Price vs 200-day average | +20.1% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 36.3 | Bearish |
| MACD (12,26,9) | -0.23 | Bearish |
| Bollinger band position | 9% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 8, 2026 7:40 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,752 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$12.59 is the latest print for FDMT, a move of +0.24% against yesterday's close of $12.56. Today's low and high so far: $12.19 and $12.92.
Equity value comes to $695.52M at the current price. By that measure it is number 3514 of the 3753 names in our coverage.
The year's floor is $6.96 and the ceiling $16.93. Shares are 25.6% away from that ceiling.
Our data shows no dividend paid by 4D Molecular Therapeutics over the trailing twelve months.
Of 9 analysts, 89% say buy, 11% hold and 0% sell. Price targets average $30.43, with the most cautious at $23.00 and the most optimistic at $36.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on FDMT.